February 2023 Top Biopharma Deal: Axsome – Pharmanovia for EDS Drug Sunosi
February 2023 Top Biopharma Deal Upfront
Axsome development and commercialization deal with Pharmanovia for Sunosi
Highlighted Deal Financial Comps
Date Announced:
February 22, 2023
Total Deal Value:
$167M
Upfront Cash:
$66M
Upfront Equity:
N/A
Option Payments:
N/A
Total Milestones:
$101M dev. and sales milestones
Royalties:
Undisclosed mid-twenties royalties
Cost & Profit Split:
N/A
Deal Synopsis
The Asset:
Axsome’s Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor
Deal Structure:
Development and Com. License
Partnership Features:
Collaborative Development, No Shared Cost
Deal Details:
-
Axsome granted Pharmanovia exclusive rights to develop and commercialize Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor in Europe and certain Middle East and North Africa (MENA) countries for the treatment of excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
-
Pharmanovia will be responsible for marketing Sunosi in Europe and MENA regions and will assume responsibility for all local clinical and regulatory activities.
-
Axsome will receive $66M up front and is eligible for up to $101M in sales and other milestones, plus undisclosed mid-twenties royalties.
Last Month:
Congrats to Axsome and Pharmanovia for landing DealForma’s February 2023 Top Biopharma Deal. Last month’s Deal of the Month was Hutchmed – Takeda for cancer drug fruquintinib. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...